United Therapeutics Corporation (UTHR)
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
United Therapeutics Corporation is a Healthcare company with a market capitalization of $21.87B and a trailing P/E ratio of 18.3.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $5.82 | $6.86 | -15.2% |
| Q4 2025 | February 25, 2026 | $7.70 | $7.10 | +8.5% |
| Q3 2025 | October 29, 2025 | $7.16 | $6.96 | +2.9% |
| Q2 2025 | July 30, 2025 | $6.41 | $7.30 | -12.2% |
| Q1 2025 | April 30, 2025 | $6.63 | $6.54 | +1.4% |
| Q4 2024 | February 26, 2025 | $6.19 | $6.27 | -1.2% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 2,088,748 | 4.43% | 5.5 | -1.4% |
| June 30, 2026 | 2,117,787 | 4.49% | 2.9 | +3.2% |
| June 15, 2026 | 2,052,888 | 4.35% | 4.6 | -6.3% |
| May 29, 2026 | 2,191,540 | 4.64% | 4.5 | -4.9% |
| May 15, 2026 | 2,303,877 | 4.88% | 5.0 | -5.9% |
| April 30, 2026 | 2,449,350 | 5.11% | 6.5 | -9.4% |
| April 15, 2026 | 2,703,199 | 5.64% | 4.8 | -4.7% |
| March 31, 2026 | 2,837,307 | 5.92% | 4.1 | -0.3% |
Other Drug Manufacturers - Specialty & Generic Stocks
Frequently Asked Questions
What is United Therapeutics Corporation's market cap?
As of August 13, 2026, United Therapeutics Corporation (UTHR) has a market capitalization of $21.87B.
What is United Therapeutics Corporation's P/E ratio?
United Therapeutics Corporation trades at a trailing price-to-earnings (P/E) ratio of 18.3. Its forward P/E is 18.6.
Does United Therapeutics Corporation pay a dividend?
United Therapeutics Corporation does not currently pay a dividend.
What sector is UTHR in?
United Therapeutics Corporation is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
What is United Therapeutics Corporation's short interest?
As of the July 15, 2026 FINRA settlement, 2,088,748 UTHR shares were sold short, or 4.43% of shares outstanding. Days to cover: 5.5. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was United Therapeutics Corporation's revenue?
In its latest reported fiscal year (ending December 31, 2025), United Therapeutics Corporation reported revenue of $3.18B and net income of $1.33B.
Ask your own questions about UTHR
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.